Replimune Group Inc (NASDAQ:REPL), a biotechnology company specializing in oncolytic immunotherapy for cancer treatment with a current market capitalization of $803 million, has been making ...

You don’t have to have a student at East Elementary to know the name Brian DeMarco. The fourth-grade teacher has contributed ...

DelveInsight's“Ocular melanoma Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Ocular melanoma, historical and forecasted epidemiology as well ...

Among the 55 novel drugs that crossed the regulatory finish line last year were notable new mechanisms of action, coming ...

IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of ...

Immunocore Holdings PLC has unveiled its strategic priorities for 2025, including plans to expand access to its Kimmtrak ...

The firm is expanding its melanoma portfolio while launching new trials of T-cell receptor therapies in oncology, infectious disease, and autoimmune disease.

In 2025, the Company’s priorities will be: Building a melanoma franchise – reaching more metastatic uveal melanoma (mUM) patients and delivering KIMMTRAK’s lifecycle management program through two ...

Group announced that the first patients have been enrolled in studies evaluating RP2 in two different settings: checkpoint ...

Do you have blue eyes? We talked to experts to discover curious facts about baby blues, including whether your biological ...

The following is a summary of “Clinical and pathological characterization of tebentafusp-associated skin toxicity: A cohort ...

In contrast to many other cancer types, UM is often diagnosed based on clinical examinations without histological assessment. 6 Ophthalmologists and ophthalmic oncologists use various techniques ...